Reagents and Bioinformatics analysis

CPV: Laboratory reagents

Procedure method

Award procedure without prior publication of a call for competition

Legal basis

CELEX · 32014L0024 Public Contracts Regulations 2015 (Directive 2014/24/EU)

Procurement category

Goods

Notice status

Awarded without competition

Procurement threshold

Unspecified in notice

Regulatory regime

Standard

Commercial structure

Stand-alone contract (no framework)

Competition type

Direct award (no call for competition)

GPA / WTO covered

Unspecified in notice

Recurring procurement

Unspecified in notice

First published

23 Jul 2025, 14:25 BST

Last source update

23 Jul 2025, 14:25 BST

Authority reference

OC007-25

FTS notice number

2025/S 000-042406

Classification (CPV)

Laboratory reagents

Delivery area

Scotland (UKM50)

Official registry OCID

ocds-h6vhtk-0564ab Find a Tender

Why no open competition

The works, supplies or services can be provided only by a particular economic operator due to absence of competition for technical reasons

Published justification

We have a number of services within the department that use Next Generation Sequencing (NGS) kits supplied by SOPHiA Genetics. These services are funded by National Services division (NSD) and the Aberdeen laboratory provides National services for Hereditary Breast, Ovarian and prostate cancer, Cardiac arrhythmias and Whole exome sequencing (for metabolic, gastrohepatology, chromosome breakage / inherited bone marrow failure and eye disorders) using these SOPHiA kits. These are essential established reagents used in these testing pathways, having previously undergone extensive validation processes within the laboratory. Purchase of alternative reagents would involve delay to testing as additional extensive validation work would need to be undertaken before use. An integral bioinformatics solution, SOPHiA DDM, is included in the price of these SOPHiA kits which provides cost-effective, streamlined analysis for these patient samples. In addition, SOPHiA DDM is used to analyse NGS data for other rare and inherited conditions using tailored analysis pipelines. This includes Primary Immune Deficiencies, Familial Hypercholesterolaemia and tumour testing for metastatic prostate cancer. This is charged on a cost per sample upload basis and allows clinical scientists to analyse the data in an efficient manner without the need for specialist bioinformaticians. Purchase of bioinformatics services from another provider would take a significant amount of time for the validation work required to ensure accurate results are obtained and would incur significant costs for extensive validation. Furthermore, additional staff would be required to perform the bioinformatics processes that would be required in the absence of the SOPHiA DDM platform for all of the national genetics services mentioned above. It is vital that the supply of these items is uninterrupted as any delay will impact on patient care including cancer surgery / treatments, stem cell transplants for patients with

Publisher note: (SC Ref:805164)

• SOPHiA GENETICS LtdAwarded supplier 60 Windsor Avenue, London, UK, SW19 2RRContact phoneShow contact details

No document links were published on the notice.